论文部分内容阅读
绝大多数肾转移癌患者的平均存活时间为8个月,其预后因素包括病变进展状态、原发性肿瘤和继发性肿瘤的诊断时间、转移部位及数量、体重下降和以往化疗情况.结合这些标准应用ECOG定出不同存活预后的5种危险组.138例转移性肾癌按ECOG分组:1组57例,2组49例,3组32例,4,5组无.127例IL-2治疗反应的可评价患者中23例为部分或完全反应患者(PR/CR),41例病变稳定(SD),63例病变进展(PD).所有患者开始IL-2治疗时取血液标本,取70例正常健康对照者血清,患者及对照组血清IL-6水平测定用ELIA法.可
The average survival time of most patients with renal metastatic carcinoma is 8 months. The prognostic factors include the progression status of the disease, the diagnosis time of primary and secondary tumors, the location and number of metastases, weight loss, and previous chemotherapy. These criteria use ECOG to define 5 different risk groups for survival prognosis. 138 cases of metastatic renal cell carcinoma were divided into ECOG groups: Group 1 57 cases, Group 2 49 cases, Group 3 32 cases, Group 4, 5 No. 127 IL- 2 Of the evaluable patients for the response to treatment, 23 were partial or complete responders (PR/CR), 41 were stable (SD), and 63 were progressive (PD). All patients started blood specimens when starting IL-2 therapy. 70 serum samples from normal healthy controls were taken. Serum IL-6 levels in patients and controls were measured by ELIA method.